UCAR-T (Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells)

anti-CD19/BCMA universal CAR-T cells · The First Affiliated Hospital of Zhejiang Chinese Medical University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UCAR-T (Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells), covering 2026-02-20 to 2026-02-20. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) [EARLY_Phase 1]

See pricing